On August 31, 2023 Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR, with multiple clinical stage drug programs, reported that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 – 9, 2023, at the George R. Brown Convention Center in Houston, Texas (Press release, Lantern Pharma, AUG 31, 2023, View Source [SID1234634812]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LP-284 is a small molecule with a synthetically lethal mechanism of action that preferentially damages cancer cells.. Lantern is developing LP-284 for the treatment of relapsed or refractory NHL, including Mantle Cell Lymphoma and Double Hit Lymphomas. Lantern expects to initiate Phase 1 clinical trials for LP-284 during Q4 of 2023.

Details of the poster presentation are listed below and can be found on the SOHO website. A full version of the poster will be available on Lantern’s website on September 11, 2023.

Title: LP-284 – Targeting Homologous Recombination Deficiencies in B-Cell Non-Hodgkin’s Lymphomas with the Novel Anti-Tumor Small Molecule LP-284
Date and Time: September 6, 2023, 6:00pm CT
Poster Number: ABCL-180
Presenter: Jianli Zhou, Ph.D., Lantern Pharma

Lantern’s LP-284 program has been accelerated and de-risked using AI insights and biological modeling powered by RADR. Lantern has been able to advance LP-284 from initial RADR insights regarding anti-cancer activity and potential mechanisms of action in hematological cancers, to selection of specific subtypes of lymphomas with superior response, to late-stage IND enabling studies, and initial design of first in human clinical trials in less than two years.

On August 31, 2023 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences (Press release, Merus, AUG 31, 2023, View Source [SID1234634811]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ET
Morgan Stanley 21st Annual Global Healthcare Conference: Wednesday, September 13 12:55-1:25 p.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.

On August 31, 2023 Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences (Press release, Halozyme, AUG 31, 2023, View Source [SID1234634810]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the presentations are as follow:

Event:

2023 Wells Fargo Healthcare Conference

Format:

Fireside Chat and 1×1 Meetings

Presentation Date:

Thursday, September 7, 2023

Presentation Time:

8:00 a.m. ET / 5:00 a.m. PT

Location:

Boston, MA

Event:

H.C. Wainwright 25th Annual Global Investment Conference

Format:

Fireside Chat and 1×1 Meetings

Presentation Date:

Monday, September 11, 2023

Presentation Time:

9:30 a.m. ET / 6:30 a.m. PT

Location:

New York, NY

Event:

Morgan Stanley 21st Annual Global Healthcare Conference

Format:

Fireside Chat and 1×1 Meetings

Presentation Date:

Tuesday, September 12, 2023

Presentation Time:

10:50 a.m. ET / 7:50 a.m. PT

Location:

New York, NY

Event:

Baird 2023 Global Healthcare Conference

Format:

Fireside Chat and 1×1 Meetings

Presentation Date:

Wednesday, September 13, 2023

Presentation Time:

1:25 p.m. ET / 10:25 a.m. PT

Location:

New York, NY

A live audio webcast of the Wells Fargo, H.C. Wainwright and Morgan Stanley presentations will be available in the Investor Relations section of the Company’s website. Replays of the audio webcasts will be available for 90 days following the conference.

On August 31, 2023 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, reported that it will present at the following investor conferences in September (Press release, UroGen Pharma, AUG 31, 2023, View Source [SID1234634808]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 25th Annual Global Investment Conference — September 11-13, 2023

Presentation: Tuesday, September 12th at 10:00 AM ET
Webcast Link: View Source

2023 Cantor Fitzgerald Global Healthcare Conference — September 26 – 28, 2023

Fireside Chat: Tuesday, September 26th at 8:35 AM ET
Webcast Link: View Source
Webcasts for both conferences will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 90 days.

On August 31, 2023 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will participate in a panel discussion at Citi’s 18th Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST (Press release, Ultragenyx Pharmaceutical, AUG 31, 2023, View Source [SID1234634807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the panel and fireside chat will be accessible from the company’s website at View Source